Screening for abdominal aortic aneurysm among patients referred to the vascular laboratory is cost-effective.
Screening for abdominal aortic aneurysm (AAA) in high-risk groups has been recommended based on a high prevalence of disease, while being questioned due to a high frequency of co-morbidities and inferior life-expectancy. We evaluated the long-term outcome and the cost-effectiveness of selective AAA screening among patients referred to the vascular laboratory for arterial examination.


METHODS
A total of 5,924 patients, referred to the vascular laboratory of a university hospital, were screened for AAA with ultrasound (definition: slashed circle>or=30 mm), 1993-2005. Outcome data were gathered through hospital records and the national population registry. A Markov model was used for health-economic evaluation.


RESULTS
An AAA was detected in 181 patients (mean age 72.8 years), of whom 21.5% underwent elective repair (perioperative mortality 5.1%) after 7.5 years of follow-up. Four of six patients diagnosed with AAA rupture were operated upon. Relative 5-year survival compared with the general Swedish population, controlled for age and sex, was 80.4% (95% confidence interval (CI): 70.8-88.8). The cost-effectiveness was robust in base-case (11,084 Euro/life year gained) and in sensitivity analyses of prevalence, cost and survival.


CONCLUSIONS
Patients in whom AAA was detected at selective screening had inferior long-term survival and were operated on less frequently, compared with AAA patients described in previous studies. Yet, selective screening at the vascular laboratory was cost-effective.
Mani
K
K
Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. kevin.mani@surgsci.uu.se
Alund
M
M
Björck
M
M
Lundkvist
J
J
Wanhainen
A
A
D000368:Aged; D017544:Aortic Aneurysm, Abdominal / Q000175:diagnosis* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics*; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008390:Markov Chains; D008403:Mass Screening / Q000191:economics*; D012017:Referral and Consultation; D015996:Survival Rate; D013548:Sweden